HUMAN IMMUNE RESPONSE TO POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES

嗜血杆菌的年龄相关和T无关特性 流感病毒B型荚膜多糖（HiB）和其他 入侵生物的多糖，限制了它们的保护性 在婴儿和儿童中， 由于这些被包裹的病原体而导致的疾病的发病率。 有机合成方案，结合Hib和其他荚膜 破伤风类毒素的多糖，设计，以便两者 增加免疫原性并赋予T细胞依赖性 （增强效应）对这些保护性抗原。 基于我们的， 和其他在该领域工作的人，一种结合Hib疫苗， 通过我们最初的方法，被FDA批准用于普遍使用 年龄大于18个月的儿童。 的安全性和 研究了我们的Hib-TT疫苗的免疫学特性 18个月奥尔兹，现在是两到三个月大的婴儿。 的 初步结果显示，抗体的保护水平是 在两次注射后在幼儿中诱导。 有效性 在北卡罗来纳州夏洛特的婴儿和儿童中进行的该疫苗研究 和瑞典的哥德堡正在规划中。

The age-related and T-independent properties, of Haemophilus influenzae type b capsular polysaccharide (Hib) and other polysaccharides of invasive organisms, limit their protective actions in infants and children, that age group which the highest attack rate of diseases due to these encapsulated pathogens. Organic synthetic schemes, that bound Hib and other capsular polysaccharides to tetanus toxoid, were devised in order to both increase the immunogenicity of and confer T-cell dependence (booster effect) to these protective antigens. Based upon ours, and others work in the field, a conjugated Hib vaccine, prepared by our original method, was licensed by the FDA for universal use in children older than 18 months of age. The safety and immunologic properties of our Hib-TT vaccine has been investigated in 18 month olds and now to two to three month old infants. The preliminary results show that protective levels of antibodies were induced in the young infants after two injections. Effectiveness study of this vaccine in infants and children in Charlotte, N.C. and Goteborg, Sweden are being planned.